Chelsea

Researchers are evaluating a ketamine-assisted group therapy for Spanish-speaking adults aged 18 to 64 with depression. This pilot clinical trial aims to assess whether this culturally adapted group intervention is feasible and safe in a community setting while also exploring its preliminary effects on psychiatric symptoms, wellbeing, and health behaviors. Participants must meet criteria for major depressive disorder and have moderate to severe symptoms based on a depression scale. The study involves an open-label, single-arm design where all participants receive ketamine-assisted psychotherapy delivered in a group format. The treatment is tailored specifically for Spanish-speaking adults and is provided under medical supervision. There is no placebo or comparison group in this phase 1 and 2 study. Participants will be observed and evaluated over several weeks, with key assessments occurring one week after treatment to measure feasibility and safety, and follow-up evaluations at one and twelve weeks post-intervention to examine changes in depression symptoms and overall health. Safety monitoring includes clinical evaluation by a psychiatrist and assessments related to medical history and vital signs. The total participation period extends through these follow-up visits to collect comprehensive data on the interventions impact.

Researchers are evaluating if a new screening method that uses an artificial intelligence AI algorithm to analyze fundus photographs, combined with eye pressure measurement and visual field testing, can improve glaucoma screening. This study focuses on people with diabetes, who have a higher risk of glaucoma, by adding glaucoma screening to existing diabetic eye disease DED screenings. The goal is to detect glaucoma earlier to help prevent or delay vision loss. Participants will be assigned to one of two groups. One group will have fundus photographs analyzed by AI for signs of glaucoma and diabetic retinopathy, plus their intraocular pressure measured using an Icare tonometer. If glaucoma is suspected, they will also undergo virtual reality visual field testing using the Olleyes device. The other group will receive usual care with diabetic eye disease screening only, including AI assessment for diabetic retinopathy without additional glaucoma tests. During the study, participants will have their eye images taken, eye pressure measured, and if needed, visual field tested using a headset. Researchers will track how well glaucoma is detected within one year of the initial screening. They will also evaluate the cost-effectiveness of the combined screening, participant satisfaction, and knowledge about glaucoma. The study is conducted in community health settings and aims to make glaucoma screening more accessible and integrated with routine diabetic eye care.